OnKure Therapeutics (OKUR) vs Telomir Pharmaceuticals (TELO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
OnKure Therapeutics (OKUR) has outperformed Telomir Pharmaceuticals (TELO) over the past year, losing 24.3% versus a loss of 30.3%. OnKure Therapeutics is the larger company by market cap ($93.1 million vs $84.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OKUR | TELO |
|---|---|---|
| Share price | $2.30 | $1.15 |
| Market cap | $93.14M | $84.66M |
| 1-day change | -2.13% | +2.68% |
| YTD return | -20.69% | -13.53% |
| 1-year return | -24.34% | -30.30% |
| 5-year return | -96.43% | — |
| EPS (TTM) | $-3.12 | $-1.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.38 | $1.82 |
| 52-week low | $2.13 | $0.888 |
| Distance from 52-week high | -57.25% | -36.71% |
| Analyst consensus | none | none |
| Avg. price target upside | +573.91% | +247.83% |
| Average volume | 216.96K | 97.98K |
| Shares outstanding | 40.50M | 73.62M |
| Employees | 45 | — |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About OnKure Therapeutics
OKUR stock →OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer.
Healthcare · Biotechnology · 45 employees
About Telomir Pharmaceuticals
TELO stock →Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria.
Healthcare · Biotechnology
OKUR vs TELO FAQ
Which is bigger, OnKure Therapeutics or Telomir Pharmaceuticals?
OnKure Therapeutics (OKUR) is larger, with a market capitalization of $93.14M compared with $84.66M for Telomir Pharmaceuticals (TELO).
Which stock has performed better over the past year, OKUR or TELO?
OKUR returned -24.34% over the past 12 months, compared with -30.30% for TELO (price return, excluding dividends). Past performance does not predict future results.
Are OnKure Therapeutics and Telomir Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.